J. Nieto Fontarigo (Santiago De Compostela, Spain), M. Hvidtfeldt (Lejre, Denmark)
Temporal trend of benralizumab safety profile in severe asthma: a cumulative meta-analysis
L. Calzetta (Parma, Italy), J. Ora (Rome, Italy), F. Cavalli (Rome, Italy), R. Laitano (Rome, Italy), P. Rogliani (Rome, Italy)
|   |
Reduction in work and activity impairment within 6 months of benralizumab initiation in Canadians with severe eosinophilic asthma
E. Penz (Saskatoon, Canada), S. Kayaniyil (Mississauga, Canada), B. Lancaster (Mississauga, Canada), B. Francoeur (Trois-Rivières, Canada), J. Lee (Toronto, Canada), M. Mallet (Bathurst, Canada), O. Tourin (Calgary, Canada), W. Ramesh (Edmonton, Canada), M. Mahdavian (Barrie, Canada), B. Walker (Calgary, Canada), Z. Belak (Regina, Canada), A. Thawer (Calgary, Canada), V. Dhawan (Edmonton, Canada), L. Mbuagbaw (Hamilton, Canada), S. Noorduyn (Mississauga, Canada)
| |
Influence of baseline FEV1 on improvement in severe eosinophilic asthma with mepolizumab
F. Gonzalez Barcala (Santiago de Compostela, Spain), M. Blanco-Aparicio (Galicia, Spain), A. Gómez-Bastero (Sevilla, Spain), G. Soto-Campos (Jerez, Spain), D. Bañas Conejero (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
| |
REDES study: Mepolizumab is effective in patients with severe eosinophilic asthma and comorbid NP
E. Arismendi Nunez (Barcelona, Spain), C. Cisneros (Madrid, Spain), M. Blanco-Aparicio (A Coruña, Spain), D. Bañas Conejero (Madrid, Spain), A. Moure (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
| |
Clinical effectiveness of benralizumab in clinical practice in Spain.
P. Ausin Herrero (Barcelona, Spain), A. Levy (Málaga, Spain), A. Padilla Galo (Marbella, Spain), I. Moya Carmona (Malaga, Spain), E. Luzón Alonso (Madrid, Spain), J. Sánchez Tena (Madrid, Spain), G. Resler (Madrid, Spain)
| |
Arthritis, a new adverse effect of anti-IL5 biologics in severe asthma patients?
C. Dupin (Paris, France), L. Morer (Paris, France), M. Phillips-Houlbracq (Paris, France), L. Deneuville (Paris, France), M. Lebrun (Paris, France), L. Tabeze (Paris, France), P. Juge (Paris, France), C. Taille (Paris, France)
| |
Sustained improvement of asthma control over 6 months of benralizumab treatment in Canadians with severe asthma
S. Noorduyn (Mississauga, Canada), S. Kayaniyil (Mississauga, Canada), B. Lancaster (Mississauga, Canada), B. Francoeur (Trois-Rivières, Canada), J. Lee (Toronto, Canada), M. Mallet (Bathurst, Canada), O. Tourin (Calgary, Canada), W. Ramesh (Edmonton, Canada), M. Mahdavian (Barrie, Canada), B. Walker (Calgary, Canada), Z. Belak (Regina, Canada), A. Thawer (Calgary, Canada), V. Dhawan (Edmonton, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada)
| |
Benralizumab continues to improve quality of life after 6 months of treatment in Canadians with severe eosinophilic asthma
E. Penz (Saskatoon, Canada), S. Kayaniyil (Mississauga, Canada), B. Lancaster (Mississauga, Canada), B. Francoeur (Trois-Rivières, Canada), J. Lee (Toronto, Canada), M. Mallet (Bathurst, Canada), O. Tourin (Calgary, Canada), W. Ramesh (Edmonton, Canada), M. Mahdavian (Barrie, Canada), B. Walker (Calgary, Canada), Z. Belak (Regina, Canada), A. Thawer (Calgary, Canada), V. Dhawan (Edmonton, Canada), L. Mbuagbaw (Hamilton, Canada), S. Noorduyn (Mississauga, Canada)
| |
First Outcomes of Anti-IL5 Biological Therapy in Patients with Severe Asthma in Croatia
D. Rnjak (Zagreb, Croatia), A. Štajduhar (Zagreb, Croatia), S. Popovic-Grle (Zagreb, Croatia), N. Ferara (Šibenik, Croatia), I. Jelavic (Zagreb, Croatia), M. Lampalo (Zagreb, Croatia)
| |
Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps
C. Santomasi (Bari, Italy), E. Buonamico (Bari, Italy), S. Dragonieri (Bari, Italy), E. Lulaj (Bari, Italy), L. Maselli (Bari, Italy), I. Iorillo (Bari, Italy), S. Piccinno (Bari, Italy), A. Capuano (Bari, Italy), M. Ahroud (Bari, Italy), I. Dei Lazzaretti (Bari, Italy), L. Iannuzzi (Bari, Italy), G. Carpagnano (Bari, Italy)
| |
Clinically relevant benefit of mepolizumab and benralizumab in asthma following EGPA in real-life settings
C. Desaintjean (Lyon, France), M. Nasser (Lyon, France), K. Ahmad (Lyon, France), J. Traclet (Lyon, France), S. Turquier (Lyon, France), J. Glérant (Lyon, France), V. Cottin (Lyon, France)
| |
Dual Biologic therapy- is it safe in patients with concomitant severe asthma and other immune-mediated diseases?
M. Navarrete Rouco (Barcelona (Barcelona), Spain), N. Carballo (Barcelona (Barcelona), Spain), I. Bobolea (Barcelona (Barcelona), Spain), E. Martínez-Moragón (Barcelona (Barcelona), Spain), S. Pascual.Erquicia (Barcelona (Barcelona), Spain), M. Labrador (Barcelona (Barcelona), Spain), M. Rancionero (Barcelona (Barcelona), Spain), P. Ausin (Barcelona (Barcelona), Spain)
| |
Clinical improvement in REDES study stratified by blood eosinophil reduction after mepolizumab treatment
C. Domingo Ribas (Sabadell, Barcelona, Spain), R. Díaz-Campos (Madrid, Spain), T. Hermida-Valverde (Asturias, Spain), E. Arismendi (Barcelona, Spain), D. Bañas Conejero (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
| |
Real world use of mepolizumab in Severe Asthma according to smoking status
J. García Rivero (Santander, Spain), E. Martínez-Moragón (Valencia, Spain), C. Pinedo (Madrid, Spain), N. Marina (Baracaldo, Spain), D. Bañas Conejero (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
| |
Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
S. Burkill (Singapore, Singapore), C. M. Porsbjerg (Bispebjerg, Denmark), A. Bourdin (Montpellier, France), T. N Tran (Gaithersburg, United States), N. Martin (Gaithersburg, United States), R. Katial (Gaithersburg, United States), P. Barker (Gaithersburg, United States), M. E Wechsler (Denver, United States), J. Maspero (Buenos Aires, Argentina), S. Bosnic-Anticevich (Sydney, Australia), L. Chung (Perth, Australia), G. Katsoulotos (Sydney, Australia), G. C Christoff (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria), M. Sadatsafavi (Vancouver, Canada), C. A Torres-Duque (Bogotá, Colombia), C. Ulrik (Hvidovre, Denmark), K. Dahl Assing (Aalborg, Denmark), S. Hansen (Copenhagen, Denmark), A. Altraja (Tartu, Estonia), L. A Lehtimaki (Tampere, Finland), N. G Papadopoulos (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Salvi (Pune, India), R. W Costello (Dublin, Ireland), P. Francesca (Rozzano, Italy), T. Iwanaga (Osakasayama, Japan), C. Rhee (Seoul, Republic of Korea), M. Al-Ahmad (Kuwait, Kuwait), D. Larenas-Linnemann (Ciudad de México, Mexico), J. A Fonseca (Porto, Portugal), R. Amaral (Sweden, Sweden), K. Alving (Sweden, Sweden), R. Al-Lehebi (Riyadh, Saudi Arabia), L. Perez De-Llano (Monforte, Cervo, Italy), B. Kirenga (Kampala, Uganda), M. Tsai (Taiwan, Taiwan), B. Mahboub (Sharjah, United Arab Emirates), P. E Pfeffer (London, United Kingdom), W. Henley (Singapore, Singapore), Y. Liu (Brisbane, Australia), J. Lyu (Singapore, Singapore), C. Goh (Singapore, Singapore), T. Uthaman (Singapore, Singapore), D. Price (Singapore, Singapore), J. Townend (Norwich, United Kingdom)
| |
Cost-effectiveness of benralizumab in patients with uncontrolled severe eosinophilic asthma in Spain
M. Mareque (Madrid, Spain), M. Climente (Valencia, Spain), E. Martínez-Moragon (Valencia, Spain), A. Padilla (Málaga, Spain), I. Oyagüez (Madrid, Spain), C. Touron (Madrid, Spain), C. Torres (Madrid, Spain)
| |
Effect of biological therapies on the rate of exacerbations in patients with severe eosinophilic asthma
S. Rojo-Tolosa (Granada, Spain), A. Menéndez-Lobo (Granada, Spain), C. Pérez-Ramírez (Granada, Spain), J. Sánchez-Martínez (Granada, Spain), M. González-Gutiérrez (Granada, Spain), A. Jiménez-Morales (Granada, Spain), C. Morales-García (Granada, Spain)
| |
Benralizumab leads to sustained asthma control improvement after 1 year in real-life severe asthmatics.
A. Renner (Wien, Austria), K. Marth (Wien, Austria), K. Patocka (Wien, Austria), M. Idzko (Wien, Austria), W. Pohl (Wien, Austria)
| |
Response to reslizumab in a real-life setting: biologic-naïve asthma patients versus switchers.
L. Pérez De Llano (Lugo, Spain), B. Cosío (Palma de Mallorca, Spain), I. Lobato Astiárraga (Valladolid, Spain), G. Soto Campos (Jerez, Spain), M. Alonso Tejedor (Alcorcón, Spain), N. Marina Malanda (Barakaldo, Spain), A. Padilla Galo (Marbella, Spain), I. Urrutia Landa (Galdakao, Spain), J. Michel De La Rosa (San Sebastián, Spain), I. García Moguel (MAdrid, Spain)
| |
Impact of biological therapy on cumulative corticosteroid dose reduction in patients with severe asthma.
D. Rodríguez Plaza (Barcelona (Barcelona), Spain), M. Vivas Roca (Barcelona (Barcelona), Spain), H. Cabrerizo Carreño (Barcelona (Barcelona), Spain), B. Gómez Martínez (Barcelona (Barcelona), Spain), S. Santos Pérez (Barcelona (Barcelona), Spain), M. Muñoz-Esquerre (Barcelona (Barcelona), Spain)
| |